Glaucoma Drug Clinical Trials Offer Promising Results
The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported.
The promising drug, which began clinical trials last year, is the product of a research collaboration between Peter Dosa, PhD, associate program director of the University of Minnesota College of Pharmacy’s Institute for Therapeutics Discovery & Development (ITDD) and research associate professor in the Department of Medicinal Chemistry; and professor Michael Fautsch of the Mayo Clinic.
These promising clinical trial findings continue to offer hope for those diagnosed with glaucoma, the second leading cause of blindness worldwide.
"I'm very excited that Qlaris thinks the clinical trial results are promising enough to keep investigating QLS-101," said Dosa. "The ITDD was founded to discover new therapeutics that help improve the lives of patients. This result is a key step towards accomplishing that goal.”
College of Pharmacy, firstname.lastname@example.org
Founded in 1892, the University of Minnesota, College of Pharmacy is the only pharmacy school in Minnesota, with campuses in the Twin Cities and in Duluth. The College of Pharmacy improves health through innovative education, pioneering research and interdisciplinary practice development that attends to the diverse needs of the people of Minnesota and the world.